

APOBEC3G antibody - N-terminal region
Rabbit Polyclonal Antibody
Catalog # AI10094**Specification**

APOBEC3G antibody - N-terminal region - Product Information

Application	IHC, WB
Primary Accession	O9HC16
Other Accession	O9HC16-2 , NP_068594 , NM_021822
Reactivity	Human, Pig
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	46 kDa KDa

APOBEC3G antibody - N-terminal region - Additional Information**Gene ID** 60489**Alias Symbol** HL-2, HBXBP, ASGPR2, ASGP-R2, CLEC4H2, APOBEC3G**Other Names**

DNA dC->dU-editing enzyme APOBEC-3G, 354-, APOBEC-related cytidine deaminase, APOBEC-related protein, ARCD, APOBEC-related protein 9, ARP-9, CEM-15, CEM15, Deoxycytidine deaminase, A3G, APOBEC3G

Target/Specificity

APOBEC3G is a member of the cytidine deaminase gene family. It is one of seven related genes or pseudogenes found in a cluster, thought to result from gene duplication, on chromosome 22. Members of the cluster encode proteins that are structurally and functionally related to the C to U RNA-editing cytidine deaminase APOBEC1. It is thought that the proteins may be RNA editing enzymes and have roles in growth or cell cycle control. The protein encoded by this gene has been found to be a specific inhibitor of human immunodeficiency virus-1 (HIV-1) infectivity.

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-APOBEC3G antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.

Precautions

APOBEC3G antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

APOBEC3G antibody - N-terminal region - Protein Information**Name** APOBEC3G {ECO:0000303|PubMed:14557625, ECO:0000312|HGNC:HGNC:17357}

Function

DNA deaminase (cytidine deaminase) which acts as an inhibitor of retrovirus replication and retrotransposon mobility via deaminase- dependent and -independent mechanisms (PubMed:12808465, PubMed:16527742, PubMed:17121840, PubMed:18288108, PubMed:18849968, PubMed:19153609, PubMed:21123384, PubMed:22791714, PubMed:25542899). Exhibits potent antiviral activity against Vif-deficient HIV-1 (PubMed:12167863, PubMed:12859895, PubMed:14557625, PubMed:20219927, PubMed:21835787, PubMed:22807680, PubMed:22915799, PubMed:23097438, PubMed:23152537, PubMed:31397674). After the penetration of retroviral nucleocapsids into target cells of infection and the initiation of reverse transcription, it can induce the conversion of cytosine to uracil in the minus-sense single-strand viral DNA, leading to G-to-A hypermutations in the subsequent plus-strand viral DNA (PubMed:12808465, PubMed:12808466, PubMed:12809610, PubMed:12970355, PubMed:14528300, PubMed:22807680). The resultant detrimental levels of mutations in the proviral genome, along with a deamination-independent mechanism that works prior to the proviral integration, together exert efficient antiretroviral effects in infected target cells (PubMed:12808465, PubMed:12808466, PubMed:12809610, PubMed:12970355, PubMed:14528300). Selectively targets single-stranded DNA and does not deaminate double-stranded DNA or single- or double-stranded RNA (PubMed:12808465, PubMed:12809610, PubMed:12970355, PubMed:14528300). Exhibits antiviral activity also against simian immunodeficiency viruses (SIVs), hepatitis B virus (HBV), equine infectious anemia virus (EIAV), xenotropic MuLV-related virus (XMRV) and simian foamy virus (SFV) (PubMed:15031497, PubMed:16378963, PubMed:18448976, PubMed:19458006, PubMed:20335265). May inhibit the mobility of LTR and non-LTR retrotransposons (PubMed:16527742).

Cellular Location

Cytoplasm. Nucleus Cytoplasm, P-body. Note=Mainly cytoplasmic (PubMed:16527742,

PubMed:16699599, PubMed:21835787). Small amount are found in the nucleus (PubMed:18667511). During HIV-1 infection, virion-encapsidated in absence of HIV-1 Vif (PubMed:12859895)

Tissue Location


Expressed in spleen, testes, ovary and peripheral blood leukocytes and CD4+ lymphocytes. Also expressed in non-permissive peripheral blood mononuclear cells, and several tumor cell lines; no expression detected in permissive lymphoid and non-lymphoid cell lines Exists only in the LMM form in peripheral blood-derived resting CD4 T- cells and monocytes, both of which are refractory to HIV-1 infection LMM is converted to a HMM complex when resting CD4 T-cells are activated or when monocytes are induced to differentiate into macrophages. This change correlates with increased susceptibility of these cells to HIV-1 infection.

APOBEC3G antibody - N-terminal region - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

APOBEC3G antibody - N-terminal region - Images



APOBEC3G antibody - N-terminal region (AI10094) in Human Stomach cells using Immunohistochemistry
Human Stomach



90 kDa_
60 kDa_
42 kDa_
32 kDa_
23 kDa_

APOBEC3G antibody - N-terminal region (A110094) in Human Daudi cells using Western Blot
WB Suggested Anti-APOBEC3G Antibody Titration: 0.2-1 µg/ml
ELISA Titer: 1:1562500
Positive Control: Daudi cell lysate

APOBEC3G antibody - N-terminal region - Background

This is a rabbit polyclonal antibody against APOBEC3G. It was validated on Western Blot and immunohistochemistry by Abgent. At Abgent we manufacture rabbit polyclonal antibodies on a large scale (200-1000 products/month) of high throughput manner. Our antibodies are peptide based and protein family oriented. We usually provide antibodies covering each member of a whole protein family of your interest. We also use our best efforts to provide you antibodies recognize various epitopes of a target protein. For availability of antibody needed for your experiment, please inquire (sales@abgent.com).